Abstracts Archive - Page 274 of 2607 - ACR Meeting Abstracts

Abstract Number: 0664 • ACR Convergence 2024
Impact of Hydroxychloroquine and Belimumab on Early Glucocorticoid Reduction in New-Onset Systemic Lupus Erythematosus: A Retrospective Analysis of Risk and Protective Factors
Takehiro Nakai¹, Sho Fukui², Yukihiko Ikeda³, Hiromichi Tamaki⁴, Mitsumasa Kishimoto⁵ and Masato Okada⁴, ¹St. Luke's International Hospital, Tokyo, Tokyo, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³St Luke's international hospital in Japan, Tokyo, Japan, ⁴St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Glucocorticoid is a critical treatment option for systemic lupus erythematosus (SLE). However, long-term use is associated with numerous side effects and an increased risk…
Abstract Number: 0603 • ACR Convergence 2024
Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry
Jakub Závada¹, Jana Baranová², Karel Pavelka¹, Jiří Vencovský³, Pavel Horak⁴, Kateřina Kusalová² and Ladislav Šenolt³, and collaborators of the ATTRA registry, ¹Institute of Rheumatology and Charles University, Praha, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic
Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
Abstract Number: 0661 • ACR Convergence 2024
Validity, Reliability and Responsiveness of Lupus Impact Tracker and LupusPRO: AURORA Trial
Meenakshi Jolly¹, Matt Truman², Ronald Flauto³ and Kathryn Dao⁴, and AURORA, ¹Rush University Medical Center, Chicago, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals, Rockville, MD, ⁴Aurinia Pharmaceuticals, Dallas
Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…
Abstract Number: 0660 • ACR Convergence 2024
Hydroxychloroquine Users at Lower Risk of Kidney Function Decline in Lupus Nephritis
Shivani Garg¹, Brad Rovin², Brad Astor¹, Tripti Singh¹, Lexie Kolton¹, Callie Saric¹, S. Sam Lim³ and Christie Bartels⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²The Ohio State University, Columbus, OH, ³Emory University, Atlanta, GA, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone in treatment of systemic lupus erythematosus (SLE), yet its role in preventing kidney function decline in lupus nephritis (LN)…
Abstract Number: 0634 • ACR Convergence 2024
Clinical Relevance of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Predicting Lupus Outcomes: A 5-Year Longitudinal Cohort Study
Hyemin Jeong¹, Ji-Hyoun Kang¹, Sung-Eun Choi², Dong-Jin Park³ and Shin-Seok Lee⁴, ¹Chonnam National University Hospital, Gwangju, South Korea, ²Chonnam National University Medical School & Hospital, Gwangju, South Korea, ³Chonnam National University Medical School and Hospital, Gwangju, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) is a newly developed tool for assessing disease activity in SLE patients. Despite external validation in diverse…
Abstract Number: 0468 • ACR Convergence 2024
Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks
David Stevens¹, Lene Sundbakk², Amirhossein Kazemi², Marte Heiberg³, Tuulikki Sokka-Isler⁴, Bjorn Gudbjornsson⁵, Kristina Lend⁶, Anna Rudin⁷, Michael Nurmohamed⁸, Jon Lampa⁹, Merete Hetland¹⁰, Mikkel Ostergaard¹¹, Ronald Van Vollenhoven¹², Tillmann Uhlig², Espen Haavardsholm² and Hilde Hammer³, ¹St. Olavs hospital, Trondheim, Norway, ²Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁴University of Eastern Finland, Faculty of Health Sciences, Jyvaskyla, Finland, ⁵Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ⁶Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ⁷Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ⁸Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁹Karolinska University Hospital, Hässelby, Sweden, ¹⁰Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ¹¹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ¹²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Plasma calprotectin is a sensitive biomarker of inflammation in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Calprotectin has not…
Abstract Number: 0595 • ACR Convergence 2024
bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
Sélina HANNA ABDELMASSIH¹, Tiphaine DUJARDIN², Athan BAILLET¹, Philippe GAUDIN¹ and Xavier ROMAND¹, ¹Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France, ²Hôpital Reine Hortense, Aix-les-Bains, France
Background/Purpose: During the last two decades we’ve witnessed the rising use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of psoriatic arthritis (PsA), leaving…
Abstract Number: 0623 • ACR Convergence 2024
Select Patient Reported Outcome Measure Domains Enhance Immune Mediator Based Indexes That Inform Flare Risk and Disease Activity in Systemic Lupus Erythematosus
Melissa Munroe¹, Daniele DeFreese², Adrian Holloway², Mohan Purushothaman², Wade DeJager³, Susan Macwana³, Joel Guthridge⁴, Stan Kamp³, Nancy Redinger³, Teresa Aberle⁴, Eliza Chakravarty⁴, Cristina Arriens⁴, Yanfeng Li⁵, hu Zeng⁵, Uma Thanarajasingam⁵, Judith James⁴ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Mayo Clinic, Rochester
Background/Purpose: We have recently validated a plasma Lupus Flare Risk Index (L-FRI; Munroe et al. Ann Rheum Dis. 2024. 83 [Supp 1]: 402) and Lupus…
Abstract Number: 0477 • ACR Convergence 2024
The Global Prevalence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Hari Prasanna¹, Charles Inderjeeth², Johannes Nossent³ and KHALID ALMUTAIRI⁴, ¹University of Western Australia, Perth, Western Australia, Australia, ²SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia, ³University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ⁴The University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of rheumatoid arthritis (RA) that severely impacts the health outcomes of RA patients. Despite this, the…
Abstract Number: 0616 • ACR Convergence 2024
Disparities in Health-Related Quality of Life Among Patients with Systemic Lupus Erythematosus
Victoria Delk¹, Dulaney Wilson², Gary Gilkeson², Jim Oates² and Diane Kamen², ¹Medical University of South Carolina, North Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with the potential to severely diminish patients' quality of life (QoL). SLE disproportionately affects young…
Abstract Number: 0671 • ACR Convergence 2024
Effect of Litifilimab on Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) Subcomponents and Physician Global Assessment–Skin (PGA–Skin) in Patients with Cutaneous Lupus Erythematosus (CLE) in a Phase 2 Study
Victoria Werth¹, Joseph F. Merola², Qianyun Li³, Weihong Yang³ and Catherine Barbey⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²UT Southwestern Medical Center, Dallas, TX, ³Biogen, Cambridge, MA, ⁴Biogen, Baar, Switzerland
Background/Purpose: In the randomized, placebo-controlled Phase 2 LILAC study of litifilimab (NCT02847598), Part B (participants with active CLE with/without SLE) met its primary endpoint of…
Abstract Number: 0604 • ACR Convergence 2024
Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024
Mahum Mirza¹, Jean Liew², Michael Putman³ and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Treatment options for psoriasis or psoriatic arthritis (PsA) have expanded in the past decade. Secular trends in biologic disease modifying antirheumatic drug (bDMARD) prescribing…
Abstract Number: 0649 • ACR Convergence 2024
Urinary Acetylated Albumin as a Biomarker of Nephritis in Patients with Systemic Lupus Erythematosus
Yeo-Jin Lee¹, Eun-Ju Lee², Minji Kim³, Mi-Ra Cho⁴, Soo Min Ahn³, Seokchan Hong⁴, Ji Seon Oh⁴, Chang-Keun Lee⁴, Bin Yoo⁴ and Yong-Gil Kim³, ¹Asan medical center, Seoul, South Korea, ²Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea, ³Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea, ⁴Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multi-organ systems, particularly the kidneys. Urine is an ideal source of SLE biomarkers…
Abstract Number: 0523 • ACR Convergence 2024
Distinct Peripheral Blood Immune Cell Sub-population Signatures at Baseline of Tofacitinib or Adalimumab Initiation Are Associated to Clinical Responses at 6 Months
Panagiota Goutakoli¹, Eirini Sevdali¹, Elpida Neofotistou-Themeli¹, Argyro Repa², Nestor Avgoustidis³, Sofia Pitsigavdaki⁴, Eleni Kalogiannaki², George Bertsias⁵, Nikolaos Paschalidis⁶, Panayotis Verginis⁷ and Prodromos Sidiropoulos⁸, ¹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation, Heraklion, Greece, ²University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ³University Hospital, Rheumatology and Clinical Immunology,, Heraklion, Greece, ⁴Rheumatology and Clinical Immunology, University of Crete School of Medicine, Heraklion, Greece, Heraklion, Greece, ⁵Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology, Heraklion, Greece, ⁶Biomedical Research Foundation, Academy of Athens, Athens, Greece, ⁷Medical School, University of Crete, Heraklion, Crete, Greece, ⁸University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece
Background/Purpose: Biomarkers to predict response to tofacitinib or adalimumab are not clinically available. Herein we aimed to characterize peripheral blood immune cell subsets with a…
Abstract Number: 0515 • ACR Convergence 2024
Scavenging Isolevuglandins with 2-HOBA Decreases In Vitro Neutrophil Extracellular Traps in Cells from Patients with Rheumatoid Arthritis
Olivia Posey, Anastasiia Phothisane, Phicharmon Kulapatana and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Neutrophils contribute to the innate immune response of killing pathogens through the formation of neutrophil extracellular traps (NETs), which is also called NETosis. NETosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].